Alloy Therapeutics, Inc.

AI/ML is reshaping antibody discovery — not by replacing the lab, but by strengthening how decisions are made across selection, developability, and optimization. On March 31, Alloy will share how integrated data infrastructure and high-throughput experimental feedback enable AI/ML workflows to inform real discovery programs.

Models alone do not drive impact. Integration does. Join Alloy’s data science and machine learning leadership for a practical discussion on how structured datasets, high-throughput screening, and closed-loop workflows determine whether AI/ML meaningfully informs antibody discovery.

How does AI/ML actually inform candidate selection and developability decisions? On March 31, Alloy will walk through production-grade workflows that pair predictive models with dense experimental feedback — and discuss the datasets required to support reliable generative approaches across targets.

For discovery leaders evaluating AI investments: impact depends on infrastructure, experimental density, and integration across programs. This webinar explores how AI/ML workflows inform portfolio-level decisions when embedded within structured data systems and high-throughput make-test-learn cycles.

Accelerate Antibody Optimization with Alloy’s Platform

De-Risk Your Antibody Pipeline with Alloy’s AI Tools. Save your seat for our Nov 19 webinar.